1. AB0747 The effect of certolizumab pegol on radiographic progression over 4 years of treatment in patients with psoriatic arthritis. (15th June 2017) Authors: Heijde, D van der; Fleischmann, R; Wollenhaupt, J; Deodhar, A; Bauer, L; Hoepken, B; Peterson, L; Mease, PJ Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1316 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0479 Predictors of long-term modified minimal disease activity response in peripheral spondyloarthritis patients treated with adalimumab. (15th June 2017) Authors: Coates, LC; Abraham, S; Tillett, W; Mease, PJ; Ramiro, S; Wu, T; Wang, X; Pangan, AL; Song, I-H Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 668 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0784 Effectiveness of anti-tnfs on dactylitis and enthesitis in patients with psoriatic arthritis: results from the corrona psoriatic arthritis/spondyloarthritis registry. (15th June 2017) Authors: Mease, PJ; Singh, R; Douglas, K; Hua, D; Litman, HJ; Karki, C; Griffith, J Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1331 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0510 Correlation of the routine assessment of patient index data (RAPID-3) with other psoriatic arthritis composite disease activity measures in patients receiving adalimumab. (15th June 2017) Authors: Mease, PJ; Chen, S; Ganz, F; Tillett, W Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 682 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. SAT0470 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year efficacy and safety results from phase 3 future 1 trial. (15th June 2017) Authors: Mease, PJ; Kavanaugh, A; Reimold, A; Tahir, H; Rech, J; Hall, S; Geusens, P; Pascale, P; Delicha, EM; Pricop, L; Mpofu, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 952 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OP0216 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS): a randomised, placebo-controlled, phase 3 trial. (15th June 2017) Authors: Mease, PJ; Hall, S; FitzGerald, O; Heijde, D van der; Merola, JF; Avila-Zapata, F; Cieślak, D; Graham, D; Wang, C; Menon, S; Hendrikx, T; Kanik, KS Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. THU0386 Use of biologics and nsaids in treating patients with axial spondyloarthritis in the us-based corrona psoriatic arthritis/spondyloarthritis (PSA/SPA) registry. (15th June 2017) Authors: Mease, PJ; Heijde, D van der; Karki, C; Liu, M; Pandurengan, R; Park, Y; Greenberg, JD Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 352 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. OP0222 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 104 weeks results from a phase 3 trial, future 2. (15th June 2017) Authors: McInnes, IB; Mease, PJ; Ritchlin, C; Rahman, P; Gottlieb, A; Kirkham, B; Kajekar, R; Delicha, EM; Pricop, L; Mpofu, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. FRI0489 Certolizumab pegol is associated with long-term improvements in patient-reported outcomes in psoriatic arthritis: 4-year outcomes from the rapid-psa study. (15th June 2017) Authors: Gladman, D; Fleischmann, R; Harris, K; Peterson, L; Mease, PJ Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 673 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. FRI0494 Secukinumab provides rapid and sustained pain relief in psoriatic arthritis: 2-year results from the future 2 study. (15th June 2017) Authors: McInnes, IB; Mease, PJ; Schett, G; Kirkham, B; Strand, V; Williams, N; Fox, T; Pricop, L; Jugl, S; Gandhi, KK Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 675 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗